It is estimated that about 11% of the population suffers from migraine. Effective therapeutic options, especially for prophylaxis, are therefore urgently needed. Study results now also confirm long-term efficacy for erenumab.
It is estimated that about 11% of the population suffers from migraine. Effective therapeutic options, especially for prophylaxis, are therefore urgently needed. Study results now also confirm long-term efficacy for erenumab.
Input your search keywords and press Enter.